Carcinoid Tumor
A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
Subtype terms (1)
More specific conditions that are subtypes of Carcinoid Tumor in the MeSH hierarchy.
- Malignant Carcinoid Syndrome
11 drugs (9 approved, 2 experimental)
Drugs by status
Approved for this indication (1)
Phase 3 trials (8)
Phase 2 trials (34)
- gallium-68-dotatate
- 90y-dota-tyr3-octreotide
- axitinib
- conatumumab
- ganitumab
- fluorouracil
- nintedanib
- ramucirumab
- nivolumab
- pembrolizumab
- leucovorin
- somatostatin
- ibrutinib
- lanreotide
- quarfloxin
- ipilimumab
- sunitinib
- pertuzumab
- rocuronium
- netazepide
- dotatoc-90y
- ga-68-dota-toc
- 90-yttrium
- aflibercept
- amino acids
- oxaliplatin
- erlotinib
- epothilone
- lutetium dotatate lu-177
- ab154
- +4 more
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (14)
- Advanced Accelerator Applications
- Genentech
- Sanofi
- Ipsen
- Novartis
- Lexicon Pharmaceuticals
- The Christie NHS Foundation Trust
- National Cancer Institute (NCI)
- Southwest Oncology Group
- University of California, San Francisco
- Vancouver Coastal Health
- European Organisation for Research and Treatment of Cancer
- Pierrel Research
- University of Western Ontario
Organization Involved with Phase 2 Indications (49)
- Molecular Insight Pharmaceuticals
- Bristol-Myers Squibb
- Amgen
- Merck
- Pharmacyclics
- Eli Lilly
- Exelixis
- Pfizer
- CASI Pharmaceuticals, Inc.
- Endo Pharmaceuticals
- Cylene Pharmaceuticals
- National Institutes of Health (NIH)
- Boston University
- Cancer Biotherapy Research Group
- University of London
- Cornell University
- Harvard University
- Eastern Cooperative Oncology Group
- Federation Francophone de Cancerologie Digestive
- University of Washington
- Johns Hopkins University
- New York University
- Northwestern University
- Norwegian University of Science and Technology
- Ochsner Health System
- Ohio State University
- Seoul National University
- Stanford University
- University of Iowa
- University of South Florida
- +19 more
Organization Involved with Phase 1 Indications (12)
Organization Involved with Other Experimental Indications (3)